Andrographolide (Diterpenoid)

Andrographolide is a bitter diterpenoid lactone extracted from Andrographis paniculata that exhibits anti-inflammatory and immunomodulatory properties. It works primarily by inhibiting NF-κB signaling pathways and modulating cytokine production.

Origin & History

Andrographolide is a diterpenoid lactone extracted from the leaves and stems of Andrographis paniculata, a herbaceous plant native to India, China, and Southeast Asia. This white crystalline compound constitutes 1-6% of the dry weight of A. paniculata leaves and is typically isolated through solvent extraction followed by purification.

Historical & Cultural Context

Known as 'King of Bitters' or Chuanxinlian, Andrographis paniculata has been used in Ayurvedic and Traditional Chinese Medicine for over 2,000 years to treat fevers, infections, digestive issues, and inflammation. Traditional preparations included decoctions or extracts for respiratory infections, malaria, and liver disorders.

Health Benefits

• Reduces rheumatoid arthritis symptoms: Clinical trial (n=60) showed decreased rheumatoid factor, IgA, and complement C4 levels (moderate evidence)
• Improves immune function in HIV: Increased CD4+ lymphocyte counts from 405 to 501 cells/mm³ in HIV patients, though viral load unchanged (preliminary evidence)
• Accelerates respiratory infection recovery: RCT (n=152) demonstrated faster symptom resolution compared to placebo (moderate evidence)
• Anti-inflammatory effects: Inhibits NF-κB, reducing TNF-α, IL-6, IL-1β, and other inflammatory markers (strong preclinical evidence)
• Low adverse event profile: Meta-analysis of 9,490 participants showed only 4.04% mild adverse events across 262 studies (strong safety evidence)

How It Works

Andrographolide inhibits nuclear factor-κB (NF-κB) translocation, reducing pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. It also modulates T-lymphocyte function by enhancing CD4+ cell proliferation while suppressing autoimmune responses. The compound interferes with cyclooxygenase-2 (COX-2) expression and nitric oxide synthase activity.

Scientific Research

Clinical evidence includes a randomized placebo-controlled trial in 60 rheumatoid arthritis patients showing symptom relief, and an RCT of 152 patients with acute respiratory infections demonstrating faster recovery (PMID: 19408036). A comprehensive safety analysis of 262 studies including 125 RCTs with 9,490 participants confirmed low adverse event rates of 4.04%, primarily mild events.

Clinical Summary

A randomized controlled trial with 60 rheumatoid arthritis patients demonstrated significant reductions in rheumatoid factor, IgA levels, and complement C4 after andrographolide treatment. HIV research showed CD4+ lymphocyte counts increased from 405 to 501 cells/mm³, though viral loads remained unchanged. Additional studies suggest benefits for upper respiratory infections, but sample sizes remain relatively small. Evidence quality ranges from preliminary to moderate across different conditions.

Nutritional Profile

Andrographolide is a bicyclic diterpenoid lactone compound (molecular formula C20H30O5, molecular weight 350.45 g/mol), not a nutritional ingredient in the conventional macronutrient/micronutrient sense. It contains no proteins, carbohydrates, fats, vitamins, or minerals. Primary bioactive constituents: Andrographolide (principal active compound, typically 0.5–6% dry weight in Andrographis paniculata leaves and aerial parts); deoxyandrographolide and neoandrographolide (related diterpenes, present at lower concentrations ~0.1–1% dry weight); 14-deoxy-11,12-didehydroandrographolide (minor diterpenoid). In standardized extracts, andrographolide concentration is typically 10–98% depending on purification grade; commercial supplements commonly standardized to 10–30% andrographolide content. Bioavailability notes: oral bioavailability of pure andrographolide is relatively low (~10–20%) due to poor aqueous solubility (approximately 2.7 mg/mL in water) and first-pass metabolism; peak plasma concentration (Tmax) reached within 1.5–2 hours post-ingestion; half-life approximately 6–8 hours; absorption enhanced by lipid-based formulations or piperine co-administration; undergoes hepatic sulfate and glucuronide conjugation; primary metabolites include andrographolide-19-β-D-glucoside and sulfonate derivatives. Fiber, mineral, and vitamin content are negligible in isolated compound form.

Preparation & Dosage

Clinically studied doses range from 1,500-2,000 mg/day of andrographolide for 6 weeks, or standardized A. paniculata extracts providing 53-107 mg andrographolide daily (from 1,000-2,000 mg extract containing 10-50% andrographolide). HIV studies used escalating doses from 5-20 mg/kg body weight. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Boswellia serrata, Quercetin, Resveratrol, Green tea extract

Safety & Interactions

Common side effects include gastrointestinal upset, nausea, and bitter taste at therapeutic doses. Andrographolide may interact with immunosuppressive medications and anticoagulants due to its effects on immune function and potential bleeding risk. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with autoimmune conditions should consult healthcare providers before use.